Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 1963-1969

  Tariq Mahmood, S ^a   Agresta, Samuel ^a   Vigil, Carlos E ^a   Zhao, Xiuhua ^a   Han, Gang ^a   D'Amato, Gina ^a   Calitri, Ciara E ^a   Dean, Michelle ^a   Garrett, Christopher ^a   Schell, Michael J ^a   Antonia, Scott ^a   Chiappori, Alberto ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

progression free rate; soft tissue sarcoma; sunitinib malate; survival; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

SUNITINIB;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEART LEFT VENTRICLE FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT DURATION;

DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; INDOLES; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRROLES; RECURRENCE; RETREATMENT; SARCOMA; SURVIVAL RATE;

EID: 80051631789     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25843     Document Type: Article

References (27)

1. Weiss SW, Goldblum JR,. Enzinger and Weiss's soft tissue tumors. St. Louis, MO: Mosby, 2001.
2. Cruz AB, Jr, Thames EA, Jr, Aust JB, Metter G, Ramirez G, Fletcher WS, Altman SJ, Frelick RW, Hill GJ, II,. Combination chemotherapy for soft-tissue sarcomas: a phase III study. J Surg Oncol 1979; 11: 313-23. (Pubitemid 9215214)
3. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR,. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-75. (Pubitemid 23199129)
4. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, Van Glabbeke M, van Oosterom A,. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537-45.
5. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M,; Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008; 34: 339-47.
6. Toma S, Palumbo R, Sogno G, Venturino A, Santi L,. Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. Ann Oncol 1992;(3 Suppl 2): S119-23.
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80. (Pubitemid 34879334)
8. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, Casali PG, Pierotti MA, Pilotti S,. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 2004; 10: 938-43. (Pubitemid 38198893)
9. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM,. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004; 91: 242-7. (Pubitemid 38233972)
10. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38. (Pubitemid 44528723)
11. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G,. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1 (2Suppl): S41-54.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
13. Miller RG,. What price Kaplan-Meier? Biometrics 1983; 39: 1077-81.
14. Meier P, Karrison T, Chappell R, Xie H,. The price of Kaplan-Meier. J Am Stat Assoc 2004; 99: 890-6. (Pubitemid 39332870)
15. Hollander M, Proschan F,. Testing to determine the underlying distribution using randomly censored data. Biometrics 1979; 35: 393-401.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
17. Van Glabbeke M, Van Glabbeke M, Verweij J, Judson I, Nielsen OS,; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-9. (Pubitemid 34185394)
18. Verweij J,. Soft tissue sarcoma trials: one size no longer fits all. J Clin Oncol 2009; 27: 3085-7.
19. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M,. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001; 8: 141-8.
20. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B,. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001; 8: 260-7. (Pubitemid 32294808)
21. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ,. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005; 25: 3591-6. (Pubitemid 41105246)
22. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T,. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001; 84: 1610-5. (Pubitemid 32612491)
23. Palman C, Bowen-Pope DF, Brooks JJ,. Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 1992; 66: 108-15.
24. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY,. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-32.
25. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-40.
26. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-60.
27. Chow LQ, Eckhardt SG,. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96. (Pubitemid 350002890)